Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Blood Advances
|
October 8, 2025
Myeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells
Juliette Ferrant, Simon Le Gallou, Francine Padonou, et al.
British Journal of Haematology
|
February 8, 2020
Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases
Guillaume Aussedat, Alexandra Traverse-Glehen, Aspasia Stamatoullas, et al.
Blood Advances
|
February 24, 2026
Myeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells
Juliette Ferrant, Simon Le Gallou, Francine Padonou, et al.
Radiology
|
April 15, 2020
Performance of CT Compared with <sup>18</sup>F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma
Fatima-Zohra Mokrane, Aiping Chen, Lawrence H Schwartz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 20, 2019
Early <sup>18</sup>F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab
Aiping Chen, Fatima-Zohra Mokrane, Lawrence H Schwartz, et al.
Journal for Immunotherapy of Cancer
|
December 5, 2019
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Guillaume Manson, Alexandre Thibault Jacques Maria, Florence Poizeau, et al.
Nature Medicine
|
September 22, 2022
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi, et al.
Blood Advances
|
October 22, 2025
Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry
Federico Erbella, Emmannuel Bachy, Guillaume Cartron, et al.
Hemasphere
|
May 8, 2026
Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group
Pierre Sesques, Guillaume Manson, Guillaume Cartron, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 7, 2024
Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines
Cédric Rossi, Guillaume Manson, Amira Marouf, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Blood Advances
|
October 8, 2025
Myeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells
Juliette Ferrant, Simon Le Gallou, Francine Padonou, et al.
British Journal of Haematology
|
February 8, 2020
Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases
Guillaume Aussedat, Alexandra Traverse-Glehen, Aspasia Stamatoullas, et al.
Blood Advances
|
February 24, 2026
Myeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells
Juliette Ferrant, Simon Le Gallou, Francine Padonou, et al.
Radiology
|
April 15, 2020
Performance of CT Compared with <sup>18</sup>F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma
Fatima-Zohra Mokrane, Aiping Chen, Lawrence H Schwartz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 20, 2019
Early <sup>18</sup>F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab
Aiping Chen, Fatima-Zohra Mokrane, Lawrence H Schwartz, et al.
Journal for Immunotherapy of Cancer
|
December 5, 2019
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Guillaume Manson, Alexandre Thibault Jacques Maria, Florence Poizeau, et al.
Nature Medicine
|
September 22, 2022
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi, et al.
Blood Advances
|
October 22, 2025
Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry
Federico Erbella, Emmannuel Bachy, Guillaume Cartron, et al.
Hemasphere
|
May 8, 2026
Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group
Pierre Sesques, Guillaume Manson, Guillaume Cartron, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 7, 2024
Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines
Cédric Rossi, Guillaume Manson, Amira Marouf, et al.
Page
of 3